Patent Strategy·About an 8-minute read

Is Faster Patent Examination Always Better? What Deferred Examination by Intel and MediaTek Means for Patent Strategy

Patent strategy is about more than protecting technology. It is about making sure intellectual property delivers business value at the right time. Examination does not always need to move as quickly as possible; what matters is securing the rights a business needs when it needs them.

Executive summary

Companies generally want their patents granted as quickly as possible. Yet the ideal examination timeline depends on when a business actually needs to exercise its patent rights.

According to the Taiwan Intellectual Property Office (TIPO), major technology companies, including Intel, MediaTek and ASML, are among those using Taiwan's expanded deferred substantive examination system. By September 2026, applicants had requested deferred examination for 443 invention patent applications, with an average deferral period of 4.27 years.

The value of deferred examination does not lie in saving fees or extending the patent term. It lies in allowing companies to retain some flexibility in their claim strategies while technologies develop and commercial opportunities become clearer. For core products approaching launch or facing active competition, accelerated examination mechanisms such as AEP and PPH may be more appropriate, with the Accelerated Examination Program for Reexamination (AEPRe) available at reexamination where the initial decision rejected only some of the claims.

An effective patent strategy should consider four business timelines: product launches, fundraising and technology transactions, international expansion, and next-generation R&D. By managing when patent rights are obtained, rather than focusing solely on how many patents are granted, companies can make better use of their patent budgets.

Does every patent need to be granted as quickly as possible?

Most companies want their patent applications granted as soon as possible. It is easy to understand why. After investing in R&D and paying patent filing fees, obtaining a patent certificate feels like a natural milestone. For management teams, the number of patents granted and the speed of examination are also straightforward measures of performance.

But consider a different perspective. Suppose a company has just developed a new technology. Its product won't launch for another three years, and the company hasn't even settled on its target market. Does it really need a granted patent within the next twelve months?

Now consider the opposite situation. A product is launching next month, and competitors are already developing similar offerings. Waiting for the ordinary examination process may not be the best approach. The difference lies in the company's business needs, rather than necessarily in the technology itself.

Patent examination doesn't always need to move as quickly as possible. What matters is securing the rights a business needs at the right time.

1. Intel, MediaTek and ASML are also using deferred examination

On November 10, 2026, TIPO released some noteworthy statistics. Effective January 1, 2026, Taiwan expanded its deferred substantive examination system for invention and design patent applications. Under the revised rules, applicants may request that substantive examination proceed at a specified later date, subject to the applicable requirements. For invention applications, the specified date may be up to five years from the filing date; for design applications, the limit is two years.

By September 2026, deferred examination had been requested for 443 invention patent applications, with an average requested deferral period of 4.27 years. Major applicants included Intel, MediaTek, Ford, ASML and Taiwan-Asia Semiconductor Corporation (TASC), with applications concentrated in image communications and semiconductor technologies. These companies are clearly not deferring examination for lack of funds.

Of course, TIPO's statistics do not disclose why individual applicants chose to defer, so we cannot infer each company's commercial motivations from these figures alone. But one point is clear: deferred examination does not necessarily indicate that a company places less importance on its patents. It is a patent management tool that major technology companies are actively using.

2. Securing patent rights is the goal, but not every patent needs to be granted immediately

Obtaining patents should not be a company's ultimate objective. Intellectual property management should help businesses build competitive advantages, increase profitability or reduce commercial risks. From this perspective, patents are intangible assets that require investment and should be evaluated in terms of their potential returns. And if patents are business assets, companies should also consider when to obtain, maintain and use them.

Consider a hypothetical example. A semiconductor equipment manufacturer is developing two technologies simultaneously.

  • Technology A has passed customer validation. Commercial shipments are expected to begin next year, and competitors are developing similar equipment.
  • Technology B concerns a key module for a next-generation manufacturing process. Its technical potential is substantial, but it remains experimental, and its commercial viability three years from now is uncertain.

For Technology A, the company may want to secure enforceable patent rights sooner to prepare for market competition and licensing negotiations. For Technology B, completing examination as quickly as possible may be less important. As development progresses, the company will identify the most valuable applications, competing product designs and technical features worth protecting.

Provided that the original application contains sufficient disclosure, the applicant may adjust its claim strategy through amendments permitted under patent law, and may also consider divisional applications where the applicable requirements are met. Newly developed technical subject matter, however, cannot simply be added to the original application; separate applications may be needed to protect subsequent improvements.

In short, the main advantage of deferred examination is not lower examination fees or a longer patent term, but the ability to preserve some flexibility in patent-related decisions while the technology and its commercial applications are still developing. For companies with long R&D cycles or business models that are still taking shape, that flexibility may be valuable.

3. Four business timelines to weigh in patent strategy

When planning applications, companies naturally focus on technical subject matter and the desired scope of protection. In our view, at least four business timelines deserve equal attention.

Product launch timeline

When will mass production begin, and when will the product reach the market? If a product is entering mass production and facing competition, the speed of obtaining enforceable rights may be critical. If development is still underway, or the direction of commercialization remains uncertain, there may be little reason for every related application to follow the same examination schedule.

Fundraising and technology transaction timeline

For startups, intellectual property can attract investors as well as protect technology. What investors care about, however, is not simply how many certificates a company holds, but whether the patents protect its core technology, create barriers to entry and support its future business model. If a company is preparing for fundraising, licensing or a merger or acquisition, securing earlier grants for key applications may help reduce uncertainty in the transaction. Conversely, accumulating granted patents for technologies whose commercial value remains unproven does not necessarily make a portfolio more valuable.

Patent prosecution timelines should serve the company's transaction objectives, rather than simply increase the number of granted patents.

International markets and patent family strategy

Corresponding applications in Taiwan, the United States, Japan and Europe do not necessarily need to be granted at the same time. Businesses can prioritize jurisdictions where they plan to enter the market soon, pursue licensing or face potential infringement risks, and arrange examination in other markets according to local procedures. There is, however, an important distinction: deferred examination does not extend the priority period for foreign filings.

International priority periods are generally twelve months for invention patents and six months for designs. PCT filing and national phase entry deadlines must also be managed separately. International protection should therefore be planned early in the filing process, rather than postponed until the Taiwanese patent is granted.

Next-generation R&D timeline

Some industries have long technology lifecycles; others introduce new product generations every year or two. When next-generation products are still under development, companies should consider whether their existing applications adequately disclose the technical variations they may eventually need to protect. For technologies that have not yet matured, retaining some examination flexibility, together with later applications covering improvements, can help a portfolio develop more systematically. These arrangements cannot replace adequate disclosure at the time of filing.

The quality of a patent portfolio ultimately depends on the application's disclosure and the strategy behind the rights being pursued. Deferred examination is simply a tool for implementing that strategy.

4. Faster has its advantages, but delaying examination comes at a cost

Deferred examination is not necessarily the more cost-effective choice.

  • Limited protection before grant. Until the grant is published by TIPO, the applicant has no enforceable exclusive rights. The application is not wholly unprotected: under Article 41 of Taiwan's Patent Act, an applicant may claim appropriate compensation after grant if a third party commercially exploited the published invention after receiving written notice, or continued such exploitation with knowledge of the published application. However, appropriate compensation is distinct from patent infringement damages, and a pending application does not support an injunction based on exclusive rights.
  • No five years of secrecy. Taiwanese invention applications are generally published eighteen months after the filing date or earliest priority date, as applicable.
  • No extra term. The standard term remains twenty years from the filing date, so waiting too long may leave a shorter period to exercise granted rights.

For applications requiring faster examination, Taiwan offers several mechanisms, including the Accelerated Examination Program (AEP), the Patent Prosecution Highway (PPH) and the Accelerated Examination Program for Reexamination (AEPRe), which applies to certain applications undergoing reexamination. TIPO's November 2026 announcement reported that qualifying AEPRe applications received their first examination result in an average of approximately 23.8 days, considerably faster than ordinary reexamination. That figure refers to the time until the first examination result; it does not mean a patent can be granted within 23.8 days of filing. AEPRe also has specific eligibility and claim amendment requirements. Companies should consider whether a procedure suits the application, whether its requirements can be met, and whether the intended scope of protection aligns with commercial objectives.

There is another perspective worth considering. As more companies use deferred examination, the market may see more published applications whose final claim scope remains uncertain. During prosecution, applicants may amend claims within the limits of the original disclosure and, where permitted, file divisional applications, potentially bringing claims closer to features found in competitors' products. For freedom-to-operate (FTO) analyses or pre-launch searches, reviewing granted patents alone may therefore be insufficient. Companies should also monitor competitors' published pending applications, including those subject to deferred examination, assess the potential scope of future rights, and consider design-around options or relevant prior art for possible invalidity challenges.

Deferred examination gives applicants flexibility, but it also creates uncertainty for competitors. Companies that know how to use the system should also know how to monitor others using it.

5. Effective patent management is about timing, not just numbers

Companies have traditionally assessed patent management through the number of applications filed, grant rates and filing costs. These measures are useful, but they are not enough. Patent management would be more closely aligned with business needs if companies considered product launches, fundraising plans, international expansion and R&D schedules from the patent proposal stage. Before filing, it is worth asking one additional question:

“When will the company need this technology to deliver business value, and what form should that value take?”

  • For core products approaching launch, obtaining enforceable rights quickly may be the priority.
  • For technologies with business models that are still evolving, preserving examination flexibility may be more useful.
  • For companies planning international expansion, foreign filing deadlines and examination schedules across jurisdictions should be part of the same strategy.

These decisions may not result in more patents, but they can help companies make better use of limited patent budgets. Move quickly when market opportunities demand it; allow more time when flexibility is valuable. Neither approach is inherently better, and the choice depends on the company's business objectives.

Companies do not need more patent certificates for the sake of having them, or faster grants for the sake of speed. They need intellectual property that delivers real value at the right time.

Make your patent timeline work for your business

How many applications in your portfolio are progressing on a schedule that genuinely supports your product launches, fundraising plans or international expansion? WISECODE helps businesses align patent applications with commercial priorities:

  • Patent portfolio review: review prosecution status, publication dates and critical deadlines of existing applications.
  • Business timeline analysis: compare prosecution schedules with product launches, fundraising and technology transactions, international expansion and R&D plans.
  • Examination strategy recommendations: evaluate whether accelerated examination (AEP or PPH, or AEPRe for eligible reexamination cases), ordinary examination or deferred substantive examination suits each application.
  • International deadline management: track priority periods, PCT deadlines and national phase entry requirements.
  • Competitor patent monitoring: monitor relevant published applications, including those subject to deferred examination, and assess potential risks to planned products.

Preparing to launch, raise capital or expand abroad?

Book a free initial consultation for a preliminary review of your patent portfolio and examination strategy.

Book a Consultation